Related Experiment Video

Updated: Aug 15, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials

Dhruv Gupte1,2, Nidhi Rashmikant Suthar2, John K MacDonald3

  • 1Department of Paediatrics, McMaster University, Hamilton, ON, Canada.

Paediatric Drugs
|August 14, 2026
PubMed

Insights

Delays in pediatric inflammatory bowel disease (pIBD) drug approvals persist, with most trials now focusing on children. Expediting new therapeutic agents for pIBD is crucial for timely patient access.

Area of Science:

  • Gastroenterology and Hepatology
  • Pediatric Clinical Trials
  • Pharmacology

Background:

  • Significant delays exist in the approval of new therapies for pediatric inflammatory bowel disease (pIBD) compared to adult IBD treatments.
  • A median delay of over 7 years is observed between adult and pediatric drug approval for IBD therapies.
  • This highlights a critical gap in timely access to advanced treatments for children with IBD.

Purpose of the Study:

  • To review and summarize the landscape of clinical trials for pediatric inflammatory bowel disease (pIBD).
  • To identify investigational and approved therapeutic agents for pIBD through analysis of trial registries.
  • To understand the current status and trends in pIBD therapeutic research.

Main Methods:

  • A cross-sectional review of ClinicalTrials.gov and ClinicalTrialsRegister.eu was performed.
  • Interventional studies involving patients under 18 years with pIBD were included.
  • Data were collected from database inception up to July 2, 2026.

Main Results:

  • 123 completed and 90 active trials met the inclusion criteria.
  • Biologics were the most studied agents, with 81 trials investigating both approved and investigational therapies.
  • Small molecule therapies were assessed in 20 trials, including JAK inhibitors and S1P receptor modulators.

Conclusions:

  • Expediting the approval process for new pIBD agents is essential for timely patient access to effective medications.
  • Novel trial designs and continued collaboration among regulatory bodies, sponsors, and researchers are vital.
  • Advancing drug approvals for pIBD requires a concerted effort to bridge the gap in pediatric therapeutic development.
Abstract

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...